InteRNA Technologies Strengthens its R&D Team

April 29, 2011

Nijmegen/Utrecht, The Netherlands, April 29th, 2011 – InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, is pleased to announce the strengthening of its R&D Team with Grégoire Prevost, PhD as Chief Development Officer and Paula van Noort, PhD as Project Manager R&D. Gregoire joined InteRNA in March of this year as member of the Management Team of the Company to manage and further develop the R&D programs towards the clinic. Grégoire brings 20+ years of translational oncology research to the Company. Prior to InteRNA, Grégoire served as the Director Oncology Translational Research & Member Oncology Portfolio MT at IPSEN, a France-based, Euronext-listed biopharmaceutical company. Paula joined InteRNA in November of 2010 to manage the R&D projects in collaboration with our academic partners. Paula brings ample experience and knowledge in lead finding and optimization to the Company. Prior to InteRNA, Paula served as team leader at Organon/Schering-Plough/Merck responsible for drug discovery ranging from target validation to selection of lead compounds in the field of contraception, fertility and hormone dependent cancers. About InteRNA Technologies B.V. InteRNA Technologies actively explores and exploits opportunities to translate its unique collection of miRNAs and miRNA discovery and validation technologies into successful diagnostic, prognostic and therapeutic applications. The Company takes an holistic approach in R&D to unravel the biological role of its proprietary miRNAs and focuses on development of miRNA-based pathway targeted therapeutics for cancer. InteRNA Technologies was incorporated in December 2006 by Aglaia Oncology Fund and has established close relationships with the research groups of its founders Edwin Cuppen, PhD, and Eugene Berezikov, PhD, of the Hubrecht Institute (Utrecht, the Netherlands), leading scientific groups in the field of miRNA research. The company further has a series of R&D partnerships with Dutch- and US-based academic hospitals and research institutes. See for more information Contact: Roel Schaapveld, PhD, MBA CEO InteRNA Technologies B.V. Phone: +31 (0)30 2532386 E-mail:

Home > News > InteRNA Technologies Strengthens its R&D Team

© 2023 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds